MicroRNA regulation and therapeutic targeting of survivin in cancer

American Journal of Cancer Research

Volumn 5, Issue 1, 2015, Pages 20-31

  Huang, Jingcao ^a,b   Lyu, Hui ^a   Wang, Jianxiang ^b   Liu, Bolin ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Cancer; miRNA; Survivin; Targeted therapy

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DOCETAXEL; EZN 3042; GATAPARSEN; MESSENGER RNA; MICRORNA; MICRORNA 143; MICRORNA 150; MICRORNA 16; MICRORNA 203; MICRORNA 218; MICRORNA 320; MICRORNA 34A; MICRORNA 494; MICRORNA 542; MICRORNA 708; MIRAVIRSEN; MRX 34; PREDNISONE; RITUXIMAB; RNA INDUCED SILENCING COMPLEX; SEPANTRONIUM BROMIDE; SURVIVIN; TERAMEPROCOL; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; BINDING SITE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; DOWN REGULATION; DRUG MECHANISM; DRUG TOLERABILITY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FUSION GENE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEPATITIS C; HUMAN; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LARYNX CARCINOMA; MELANOMA; MERKEL CELL TUMOR; METASTASIS INHIBITION; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RNA BINDING; RNA DEGRADATION; TEL AML1 GENE; TRANSCRIPTION REGULATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

EID: 84937251445     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Fulda S. Inhibitor of apoptosis proteins in hematological malignancies. Leukemia 2009; 23: 467-476.
2. Hunter AM, LaCasse EC and Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007; 12: 1543-1568.
3. Ambrosini G, Adida C and Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
4. Mahotka C, Wenzel M, Springer E, Gabbert HE and Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999; 59: 6097-6102.
5. Caldas H, Honsey LE and Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 2005; 4: 11.
6. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005; 92: 212-216.
7. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T and Inuzuka M. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 2004; 314: 902-907.
8. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-584.
9. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61-70.
10. Kanwar JR, Kamalapuram SK and Kanwar RK. Survivin signaling in clinical oncology: a multifaceted dragon. Med Res Rev 2013; 33: 765-789.
11. Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I and Reed JC. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 2003; 22: 2729-2740.
12. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, Salvesen GS, Reed JC and Altieri DC. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004; 279: 34087-34090.
13. Zaffaroni N and Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 2002; 5: 65-72.
14. Coumar MS, Tsai FY, Kanwar JR, Sarvagalla S and Cheung CH. Treat cancers by targeting survivin: just a dream or future reality? Cancer Treat Rev 2013; 39: 802-811.
15. Wang S, Huang X, Lee CK and Liu B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 2010; 29: 4225-4236.
16. Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK and Liu B. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Res 2013; 15: R101.
17. Nabilsi NH, Broaddus RR and Loose DS. DNA methylation inhibits p53-mediated survivin repression. Oncogene 2009; 28: 2046-2050.
18. Tanaka C, Uzawa K, Shibahara T, Yokoe H, Noma H and Tanzawa H. Expression of an inhibitor of apoptosis, survivin, in oral carcinogenesis. J Dent Res 2003; 82: 607-611.
19. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
20. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
21. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR and Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
22. Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, Chen Y, Deng G, Tanaka Y and Dahiya R. Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis. Clin Cancer Res 2011; 17: 5287-5298.
23. Bian K, Fan J, Zhang X, Yang XW, Zhu HY, Wang L, Sun JY, Meng YL, Cui PC, Cheng SY, Zhang J, Zhao J, Yang AG and Zhang R. MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. FEBS Lett 2012; 586: 804-809.
24. Wei W, Wanjun L, Hui S, Dongyue C, Xinjun Y and Jisheng Z. miR-203 inhibits proliferation of HCC cells by targeting survivin. Cell Biochem Funct 2013; 31: 82-85.
25. Jin J, Deng J, Wang F, Xia X, Qiu T, Lu W, Li X, Zhang H, Gu X, Liu Y, Cao W and Shao W. The expression and function of microRNA-203 in lung cancer. Tumour Biol 2013; 34: 349-357.
26. Xu D, Wang Q, An Y and Xu L. MiR203 regulates the proliferation, apoptosis and cell cycle progression of pancreatic cancer cells by targeting Survivin. Mol Med Rep 2013; 8: 379-384.
27. Yu X, Zhang X, Dhakal IB, Beggs M, Kadlubar S and Luo D. Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells. BMC Cancer 2012; 12: 29.
28. Xie H, Lee L, Caramuta S, Hoog A, Browaldh N, Bjornhagen V, Larsson C and Lui WO. MicroRNA Expression Patterns Related to Merkel Cell Polyomavirus Infection in Human Merkel Cell Carcinoma. J Invest Dermatol 2014; 134: 507-517.
29. Kumar B, Yadav A, Lang J, Teknos TN and Kumar P. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One 2012; 7: e37601.
30. Ji X, Wang Z, Geamanu A, Goja A, Sarkar FH and Gupta SV. Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells. Int J Cancer 2012; 131: 2668-2677.
31. Chen Y, Tsai YH and Tseng SH. Inhibition of cyclin-dependent kinase 1-induced cell death inneuroblastoma cells through the microRNA-34a-MYCN-survivin pathway. Surgery 2013; 153: 4-16.
32. Cao W, Yang W, Fan R, Li H, Jiang J, Geng M, Jin Y and Wu Y. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol 2013; 35: 1287-95.
33. Cao W, Fan R, Wang L, Cheng S, Li H, Jiang J, Geng M, Jin Y and Wu Y. Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells. Tumour Biol 2013; 34: 963-971.
34. Chen Y, Zhu X, Zhang X, Liu B and Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010; 18: 1650-1656.
35. Shen Z, Zhan G, Ye D, Ren Y, Cheng L, Wu Z and Guo J. MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. Med Oncol 2012; 29: 2473-2480.
36. Yoon S, Choi YC, Lee S, Jeong Y, Yoon J and Baek K. Induction of growth arrest by miR-542-3p that targets survivin. FEBS Lett 2010; 584: 4048-4052.
37. Saini S, Yamamura S, Majid S, Shahryari V, Hirata H, Tanaka Y and Dahiya R. MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res 2011; 71: 6208-6219.
38. Wang S, Huang J, Lyu H, Lee CK, Tan J, Wang J and Liu B. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis 2013; 4: e556.
39. Diakos C, Zhong S, Xiao Y, Zhou M, Vasconcelos GM, Krapf G, Yeh RF, Zheng S, Kang M, Wiencke JK, Pombo-de-Oliveira MS, Panzer-Grumayer R and Wiemels JL. TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a. Blood 2010; 116: 4885-4893.
40. Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, O'Sullivan B and Liu FF. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 2011; 71: 2381-2391.
41. Mertens-Talcott SU, Chintharlapalli S, Li X and Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 2007; 67: 11001-11011.
42. Pathi SS, Jutooru I, Chadalapaka G, Sreevalsan S, Anand S, Thatcher GR and Safe S. GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. Mol Cancer Res 2011; 9: 195-202.
43. Mertens-Talcott SU, Noratto GD, Li X, Angel-Morales G, Bertoldi MC and Safe S. Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: role of Sp transcription factors and microRNA-27a:ZBTB10. Mol Carcinog 2013; 52: 591-602.
44. Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS and Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 2010; 1: e105.
45. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS, Huang WL, Zeng YX and Shao JY. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res 2011; 71: 3552-3562.
46. Boll K, Reiche K, Kasack K, Morbt N, Kretzschmar AK, Tomm JM, Verhaegh G, Schalken J, von Bergen M, Horn F and Hackermuller J. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 2012; 32: 277-85.
47. Craig VJ, Cogliatti SB, Rehrauer H, Wundisch T and Muller A. Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis. Cancer Res 2011; 71: 3616-3624.
48. Formosa A, Lena AM, Markert EK, Cortelli S, Miano R, Mauriello A, Croce N, Vandesompele J, Mestdagh P, Finazzi-Agro E, Levine AJ, Melino G, Bernardini S and Candi E. DNA methylation silences miR-132 in prostate cancer. Oncogene 2012; 32: 127-34.
49. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I and Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010; 31: 766-776.
50. Zhang Z, Zhang B, Li W, Fu L, Zhu Z and Dong JT. Epigenetic Silencing of miR-203 Upregulates SNAI2 and Contributes to the Invasiveness of Malignant Breast Cancer Cells. Genes Cancer 2011; 2: 782-791.
51. Rauch A, Hennig D, Schafer C, Wirth M, Marx C, Heinzel T, Schneider G and Kramer OH. Survivin and YM155: how faithful is the liaison? Biochim Biophys Acta 2014; 1845: 202-220.
52. Carter BZ, Milella M, Altieri DC and Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood 2001; 97: 2784-2790.
53. Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE and Morris JC. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer 2011; 10: 35.
54. Molckovsky A and Siu LL. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol 2008; 1: 20.
55. Erba HP, Sayar H, Juckett M, Lahn M, Andre V, Callies S, Schmidt S, Kadam S, Brandt JT, Van Bockstaele D and Andreeff M. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest New Drugs 2013; 31: 1023-1034.
56. Wiechno P, Somer BG, Mellado B, Chlosta PL, Cervera Grau JM, Castellano D, Reuter C, Stockle M, Kamradt J, Pikiel J, Duran I, Wedel S, Callies S, Andre V, Hurt K, Brown J, Lahn M and Heinrich B. A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer. Eur Urol 2013; 65: 516-20.
57. Sapra P, Wang M, Bandaru R, Zhao H, Greenberger LM and Horak ID. Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide. Nucleosides Nucleotides Nucleic Acids 2010; 29: 97-112.
58. Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Muschen M and Kim YM. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 2011; 118: 2191-2199.
59. Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP, Lee L, Bhojwani D, Horton TM, Belitskaya-Levy I, Greenberger LM, Horak ID, Grupp SA, Teachey DT, Raetz EA and Carroll WL. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia 2012; 26: 271-279.
60. Raetz EA, Morrison D, Romanos-Sirakis E, Gaynon P, Sposto R, Bhojwani D, Bostrom BC, Brown P, Eckroth E, Cassar J, Malvar J, Buchbinder A and Carroll WL. A Phase I Study of EZN-3042, a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist, Administered in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL): A Report From the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. J Pediatr Hematol Oncol 2013; 36: 458-63.
61. Srivastava AK, Sharma RK, Yolcu ES, Ulker V, MacLeod K, Dinc G and Shirwan H. Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner. PLoS One 2012; 7: e48463.
62. Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H, van Rees B, Raymakers R, Schaap N and Dolstra H. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother 2013; 62: 1381-1392.
63. Safe S and Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer 2005; 41: 2438-2448.
64. Chen H, Teng L, Li JN, Park R, Mold DE, Gnabre J, Hwu JR, Tseng WN and Huang RC. Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. J Med Chem 1998; 41: 3001-3007.
65. Park R, Giza PE, Mold DE and Huang RC. Inhibition of HSV-1 replication and reactivation by the mutation-insensitive transcription inhibitor tetra-O-glycyl-nordihydroguaiaretic acid. Antiviral Res 2003; 58: 35-45.
66. Smolewski P. Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs 2008; 11: 204-214.
67. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, Kudoh M and Sasamata M. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-8021.
68. Holmes D. Cancer drug's survivin suppression called into question. Nat Med 2012; 18: 842-843.
69. Nakamura N, Yamauchi T, Hiramoto M, Yuri M, Naito M, Takeuchi M, Yamanaka K, Kita A, Nakahara T, Kinoyama I, Matsuhisa A, Kaneko N, Koutoku H, Sasamata M, Yokota H, Kawabata S and Furuichi K. Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin. Mol Cell Proteomics 2012; 11: M111 013243.
70. Yamauchi T, Nakamura N, Hiramoto M, Yuri M, Yokota H, Naitou M, Takeuchi M, Yamanaka K, Kita A, Nakahara T, Kinoyama I, Matsuhisa A, Kaneko N, Koutoku H, Sasamata M, Kobori M, Katou M, Tawara S, Kawabata S and Furuichi K. Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. Biochem Biophys Res Commun 2012; 425: 711-716.
71. Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A, Koutoku H, Takeuchi M, Brattain MG and Li F. Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol 2012; 3: 179-197.
72. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M and Sasamata M. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 2011; 102: 614-621.
73. Glaros TG, Stockwin LH, Mullendore ME, Smith B, Morrison BL and Newton DL. The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother Pharmacol 2012; 70: 207-212.
74. Arora R, Shuda M, Guastafierro A, Feng H, Toptan T, Tolstov Y, Normolle D, Vollmer LL, Vogt A, Domling A, Brodsky JL, Chang Y and Moore PS. Survivin is a therapeutic target in merkel cell carcinoma. Sci Transl Med 2012; 4: 133ra156.
75. Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, Shamsili S and Papadopoulos KP. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 2012; 118: 3128-3134.
76. Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, Lawson D, Whitman E and Gonzalez R. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 2011; 29: 161-166.
77. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A and Shamsili S. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009; 27: 4481-4486.
78. Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A and de Bono JS. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol 2012; 23: 968-973.
79. Kita A, Mitsuoka K, Kaneko N, Nakata M, Yamanaka K, Jitsuoka M, Miyoshi S, Noda A, Mori M, Nakahara T and Sasamata M. Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab. J Pharmacol Exp Ther 2012; 343: 178-183.
80. Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, Keating A and Waldmann TA. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. Blood 2013; 121: 2029-2037.
81. Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, Poondru S, Van Sant C, Keating A, Steinberg SM, Figg W and Giaccone G. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2013; 24: 2601-2606.
82. Zhang Y, Wang Z and Gemeinhart RA. Progress in microRNA delivery. J Control Release 2013; 172: 962-974.
83. Nana-Sinkam SP and Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 2013; 93: 98-104.
84. Bader AG, Brown D, Stoudemire J and Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther 2011; 18: 1121-1126.
85. Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gulla A, Tagliaferri P, Tassone P and Caraglia M. Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids 2014; 3: e194.
86. Gaca S, Reichert S, Multhoff G, Wacker M, Hehlgans S, Botzler C, Gehrmann M, Rodel C, Kreuter J and Rodel F. Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells. J Control Release 2013; 172: 201-206.
87. Gaca S, Reichert S, Rodel C, Rodel F and Kreuter J. Survivin-miRNA-loaded nanoparticles as auxiliary tools for radiation therapy: preparation, characterisation, drug release, cytotoxicity and therapeutic effect on colorectal cancer cells. J Microencapsul 2012; 29: 685-694.
88. Fukuda S and Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006; 5: 1087-1098.
89. Wahdan-Alaswad R and Liu B. "Sister" miRNAs in cancers. Cell Cycle 2013; 12: 3703-3704.
90. Ma Q, Wang X, Li Z, Li B, Ma F, Peng L, Zhang Y, Xu A and Jiang B. microRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway. Oncol Rep 2013; 29: 1652-1658.
91. Tan LP, Wang M, Robertus JL, Schakel RN, Gibcus JH, Diepstra A, Harms G, Peh SC, Reijmers RM, Pals ST, Kroesen BJ, Kluin PM, Poppema S and van den Berg A. miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Lab Invest 2009; 89: 708-716.